Binx Health announces first patients benefit from one-time tests for chlamydia and gonorrhea

The binx health io system is a fully automated qualitative test for rapid testing of chlamydia and gonorrhea DNA for female vaginal swabs at medical sites or clinical laboratoriesThese samples are collected by the clinician or the patient themselves at the clinical point of careIn the first real-world use case, the binx io platform provides one-time chlamydia and gonorrhea (the two most commonly detected sexually transmitted infections in the world) diagnosis and treatment, with the permission of Innovate UK SBRI, worked with three NHS trusts and StGeorge's College, University of LondonGeorges University of London, the "SGUL", is a joint effort to diagnose patients who may face delays of several days between infection identification and treatment, and the binxio platform is now used by clinicianstaking into account the average medical visit time in the United States 1, binxio can provide results through the time of a single medical visit (before the patient leaves the doctor's office)This presents the opportunity to test and treat millions of patients who need to be screened according to medical guidelines with accuracy comparable to those of the central laboratory, through an environment close to the patientOf the company's recently completed multicenter clinical studies of 1,523 patients, 96% of the patient samples were processed by non-laboratory personnel through binxio in a medical site settingClinical results showed that the sensitivity and specificity of female chlamydia detection were 96.1% and 99.1%, respectively, and the sensitivity and specificity of gonorrhea detection reached 100% and 99.9%, respectivelyBinx's chlamydia/gonorrhea testing was CE-certified in April 2019 and 510 (k) licensefrom the U.SFood and Drug Administration in August 2019The binx healthio chlamydia/gonorrhea test (tested using the binx healthio platform) is a fully automated qualitative test for rapid detection of chlamydia and gonorrhea DNA from female vaginal swabs at medical sites or clinical laboratoriesThese samples are collected by the clinician or the patient themselves at the clinical point of careFor those concerned about women's health, rapid testing and treatment are essentialIn women, undiscovered sexually transmitted infections can lead to a range of reproductive health problems, including infertility, pelvic inflammatory disease, ectopic pregnancy, and other complications that patients can avoid during early rapid testing in nearby locationsThe Centers for Disease Control (CDC) estimates that untreated statising infections in the United States alone cause 24,000 women to become infertile each year Guidelines from the American College of Obstetricians and Gynecologists recommend chlamydia/gonorrhea screening for all pregnant women and women trying to conceive Rapid detection and treatment of these infections can be a central tool for improving the overall reproductive health of millions of people each year Note: Cut in the original text